Research In The Improvement Of Quality Of Life In Therapy Of Cascade Primed Immune Cells Of Patients With Breast Cancer

Objective:To evaluate the effects of improvement of quality of lifeof patients with breast cancer of phaseⅡand phaseⅢafter combination of therapy of cascade primed immune cells and chemotherapy (ie, biochemotherapy).Method:1, Use COBE SpectraTM blood cell separator to collect the peripheral blood mononuclear cell (PBMC) of the patients with breast cancer, then separate 3 months in generating, inducing, activating, preparating and transfusing them in the laboratory which meet GMP.2, every patient with breast cancer require 24 transfusion in total in a course and for a interval of 3 months need repeat a course.It is best to have two course in the first year and to have a course per year after the first year.3, According to the《Breast Cancer Clinical Practice Guidelines of Chinese version of NCCN in 2008》, to determine the drugs of chemotherapy which measure the disease stage of patients with breast cancer and comprehensive situation of them and giving the cascade primed immune cells at the same time.4 The workers of the Institute of Psychology of Chinese Academy translate the EORTC QLQ-C30 (V3.0), EORTC QLQ-BR23 which developed by the EORTC (European Organization for Research and Treatment) into Chinese, then Professor Wan Chonghua of school of public health of the Kunming Medical College and Professor Tang Xueliang of the mammary department of Yunnan Tumor Hospital and others evaluate them.They have good evaluation of validity, feasibility, and some degree of responsiveness and could be assessment instrument of the patients with malignant tumors.We could use them to evaluate the improvement of quality of life of the people who accept the therapy of cascade primed immune cells.Results:1,In the comparisons of beginning and end of patients with breast cancer who never have the therapy of cascade primed immune cells in QLQ-C30 (V3.0), the value of P of 12 dimensions＜0.05 and have statistical significance,such as physical functioning (PF), role functioning (RF), emotional functioning(EF), cognitive functioning (CF) social functioning (SF), global health status (QL), fatigue (FA), nausea and vomiting (NV), Pain (PA), respiratory disorder (DY), insomnia (SL), appetite loss (AP).In QLQ-BR23,there are values of P of 4 dimensions＜0.05 and statistically significant, such as systemic therapy side effects, breast symptoms, arm symptoms, upset by hair loss.2, In the comparisons of beginning and end of patients with breast cancer who have the therapy of cascade primed immune cells in QLQ-C30 (V3.0), the value of P of 14 dimensions＜0.05 and have statistical significance,such as physical functioning (PF), role functioning (RF), emotional functioning (EF), cognitive functioning (CF), social functioning (SF), global health status (QL), fatigue (FA), nausea and vomiting (NV), pain (PA), respiratory disorder (DY), insomnia (SL), appetite loss (AP), diarrhea (DI), economic conditions (FI).In QLQ-BR23,there are 5 dimensions＜0.05 and statistically significant, such as sexual functioning, systemic therapy side effects, breast symptoms, arm symptoms, upset by hair loss.3,In the comparisons of difference of the beginning and end of the patients never having the therapy of cascade primed immune cells and having the therapy of cascade primed immune cells in QLQ-C30 (V3.0), the value of P of 11 dimensions＜0.05 and have statistical significance,such as physical functioning (PF),role functioning (RF),emotional functioning (EF) cognitive functioning (CF),social functioning (SF),global health status (QL),fatigue (FA) financial difficulties (FI),pain (PA),appetite loss (AP),nausea and vomiting (NV).In QLQ-BR23,there are 2 dimensions＜0.05 and statistically significant, such as sexual functioning,systemic therapy side effects.Conclusion:1, The therapy of ascade primed immune cells could cause obvious improvement in some dimentions of the patients with breast cancer,such as. physical functioning (PF), role functioning (RF), emotional functioning (EF), cognitive functioning (CF), social functioning (SF), global health status (QL), fatigue (FA), nausea and vomiting (NV), pain (PA), appetite loss (AP), financial difficulties (FI), systemic therapy side effects, exual functioning.2, The therapy of ascade primed immune cells could cause obvious improvement in some dimentions of the patients with breast cancer, such as dyspnoea (DY), insomnia (SL), constipation (CO), diarrhoea (DI), body image,sexual enjoyment, future perspective, breast symptoms, arm symptoms, upset by hair loss.